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ABSTRACT Use of whole-genome sequencing (WGS) for routine mycobacterial spe-
cies identiﬁcation and drug susceptibility testing (DST) is becoming a reality. We
compared the performances of WGS and standard laboratory workﬂows prospec-
tively, by parallel processing at a major mycobacterial reference service over the
course of 1 year, for species identiﬁcation, ﬁrst-line Mycobacterium tuberculosis resis-
tance prediction, and turnaround time. Among 2,039 isolates with line probe assay
results for species identiﬁcation, 74 (3.6%) failed sequencing or WGS species identiﬁ-
cation. Excluding these isolates, clinically important species were identiﬁed for 1,902
isolates, of which 1,825 (96.0%) were identiﬁed as the same species by WGS and the
line probe assay. A total of 2,157 line probe test results for detection of resistance to
the ﬁrst-line drugs isoniazid and rifampin were available for 728 M. tuberculosis com-
plex isolates. Excluding 216 (10.0%) cases where there were insufﬁcient sequencing
data for WGS to make a prediction, overall concordance was 99.3% (95% conﬁdence
interval [CI], 98.9 to 99.6%), sensitivity was 97.6% (91.7 to 99.7%), and speciﬁcity was
99.5% (99.0 to 99.7%). A total of 2,982 phenotypic DST results were available for 777
M. tuberculosis complex isolates. Of these, 356 (11.9%) had no WGS comparator due
to insufﬁcient sequencing data, and in 154 (5.2%) cases the WGS prediction was in-
determinate due to discovery of novel, previously uncharacterized mutations. Ex-
cluding these data, overall concordance was 99.2% (98.7 to 99.5%), sensitivity was
94.2% (88.4 to 97.6%), and speciﬁcity was 99.4% (99.0 to 99.7%). Median processing
times for the routine laboratory tests versus WGS were similar overall, i.e., 20 days
(interquartile range [IQR], 15 to 31 days) and 21 days (15 to 29 days), respectively
(P  0.41). In conclusion, WGS predicts species and drug susceptibility with great ac-
curacy, but work is needed to increase the proportion of predictions made.
KEYWORDS line probe assay, mycobacteria, phenotype, WGS, whole-genome
sequencing
In 2015, the World Health Organization (WHO) estimated that there were 10.4 millionnew tuberculosis (TB) cases, with 1.4 million deaths attributed directly to the disease
(1). Three percent of new cases and 20% of previously treated cases are estimated
to be resistant to one or more anti-TB drugs. Concerns over rises in the prevalence
Received 13 September 2017 Returned for
modiﬁcation 9 October 2017 Accepted 11
November 2017
Accepted manuscript posted online 22
November 2017
Citation Quan TP, Bawa Z, Foster D, Walker T,
del Ojo Elias C, Rathod P, MMM Informatics
Group, Iqbal Z, Bradley P, Mowbray J, Walker
AS, Crook DW, Wyllie DH, Peto TEA, Smith EG.
2018. Evaluation of whole-genome sequencing
for mycobacterial species identiﬁcation and
drug susceptibility testing in a clinical setting: a
large-scale prospective assessment of
performance against line probe assays and
phenotyping. J Clin Microbiol 56:e01480-17.
https://doi.org/10.1128/JCM.01480-17.
Editor Daniel J. Diekema, University of Iowa
College of Medicine
Copyright © 2018 Quan et al. This is an open-
access article distributed under the terms of
the Creative Commons Attribution 4.0
International license.
Address correspondence to T. Phuong Quan,
phuong.quan@ndm.ox.ac.uk.
* Present address: Carlos del Ojo Elias, Oxford





February 2018 Volume 56 Issue 2 e01480-17 jcm.asm.org 1Journal of Clinical Microbiology
of multidrug-resistant TB (MDR-TB) strengthen requirements for rapid, effective
diagnosis to identify drug resistance early, to target treatment effectively, and to
reduce transmission. In this context, the WHO recommends molecular diagnosis by
use of line probe assays (LPAs) (using PCR followed by hybridization) when multi-
drug resistance is suspected. A recent meta-analysis reported a high sensitivity and
speciﬁcity of LPAs for detection of MDR-TB (2). In particular, the Hain GenoType
MTBDRplus V1 and V2 assays have a sensitivity and speciﬁcity of 90% and 98%,
respectively, for detection of rifampin resistance and 89% and 99%, respectively, for
detection of isoniazid resistance (3).
There are 176 mycobacterial species (other than M. tuberculosis) published and
available online (http://www.bacterio.net/mycobacterium.html), with Mycobacterium
alsense being the most recent addition (added in 2016) (4). Given the increasing
incidence of pulmonary nontuberculous mycobacterial (NTM) infections (5, 6), correct
identiﬁcation of NTM infections versus TB is becoming crucial for the management of
clinical symptoms and treatment (7) (since NTM infections are tested and treated with
a range of agents different from those used for TB), as well as being important for the
public health response. Recent outbreaks of human disease arising from environmental
contamination with M. chimaera (8) highlight the need to understand the role of
environmental reservoirs of NTM more fully and to require accurate identiﬁcation of
NTM species isolated from clinical samples, particularly those cultured from nonpul-
monary sites, such as blood and tissues.
Molecular tests can differentiate species more accurately than phenotypic tests,
including biochemical tests, but multiple targets often exist, such as the 16S rRNA gene
(9), 16S-23S rRNA internal transcribed spacer (10), and the beta subunit of RNA
polymerase (encoded by rpoB) (11). The inability to discern differences between closely
related mycobacterial species by use of one gene has led to use of multigene methods
(12). The GenoType MTBC (Mycobacterium tuberculosis complex) and GenoType Myco-
bacterium CM/AS (common mycobacteria/additional species) assays (Hain Lifescience
GmbH, Nehran, Germany) identify species via 23S rRNA gene PCR and reverse hybrid-
ization. The assays identify 6, 23, and 14 species of mycobacteria, respectively, either
individually or by the combination of patterns detected. Concordance varies between
the CM and AS tests (13, 14), with misidentiﬁcation or lack of identiﬁcation attributed
to sequence variation in the probe region or ambiguous results. Evaluations of the
GenoType Mycobacterium assays suggest an agreement with other methods of 89%
(15).
Ongoing advances in whole-genome sequencing (WGS) of pathogens have the
potential to signiﬁcantly improve both the characterization of microbes, including
mycobacteria, and investigations of suspected outbreaks. The use of WGS in mycobac-
terial diagnosis, including detection of multidrug-resistant M. tuberculosis isolates, is
becoming a reality (16–19). Formal comparisons between WGS and standard molecular
and other laboratory techniques are therefore essential if WGS is going to become the
diagnostic test of choice.
We previously reported a pilot study demonstrating the potential of WGS for
diagnosis of mycobacterial infection (16). In the present study, we formally assessed the
agreement between WGS and standard laboratory practice in terms of NTM/MTBC
species identiﬁcation, ﬁrst-line TB resistance prediction, and turnaround time by parallel
processing of 2,171 clinical isolates from a major mycobacterial reference service over
the course of 1 year.
MATERIALS AND METHODS
The National Mycobacterial Reference Service in Birmingham, United Kingdom, provides reference
testing to determine the species of all mycobacterial cultures submitted by National Health Service (NHS)
laboratories across the Midlands and the North, with drug susceptibility testing (DST) and strain typing
for MTBC isolates. During the study, it served 26 hospitals across the Midlands, covering around 12
million people.
WGS was run in parallel against routine laboratory diagnostic workﬂows from April 2015 to March
2016. Material from liquid cultured clinical samples signaling positive in mycobacterial growth indicator
tubes (MGIT tubes; Becton Dickinson) was processed using Hain Lifesciences line probe assays to identify
Quan et al. Journal of Clinical Microbiology
February 2018 Volume 56 Issue 2 e01480-17 jcm.asm.org 2
species (using the GenoType CM test followed by the GenoType Mycobacterium MTBC or GenoType
Mycobacterium AS test, if required) and, for MTBC isolates, to assay isoniazid/rifampin drug susceptibility
(using the GenoType MTBDRplus test). MTBC isolates were also tested phenotypically with ﬁrst-line drugs
(isoniazid, rifampin, ethambutol, and pyrazinamide) following the manufacturer’s recommended proce-
dures for the MGIT 960 system. An aliquot was also removed from the MGIT tube and prepared for WGS
as previously described (20). Sequencing was attempted a maximum of twice, and data were centrally
processed using a semiautomated bioinformatics pipeline. Within the pipeline, species identiﬁcation was
conducted using Mykrobe v0.3 (21). Isolates were also mapped to a library of mycobacterial reference
genomes, and resistance predictions were made for any isolates which mapped to the MTBC reference
strain H37Rv by use of our previously validated mutation catalogue (22).
WGS results were not returned to clinicians, so individual patient management was not affected by
the study. As the WGS platform was still under development while the study was ongoing, turnaround
time was partially estimated (see below), but ﬁnal species and susceptibility predictions were based on
ﬁnal algorithms at the end of the study. Any isolates included in algorithm development were excluded
from the ﬁnal results.
Isolates with discordant routine laboratory and WGS results were regrown and reprocessed by both
methods, and the laboratory results were reviewed by an experienced microbiologist.
Statistical methods. For species identiﬁcation, WGS and LPA results were compared by binomial
exact tests, taking the latter as the gold standard. Overall accuracy estimation was based on the following
clinically important species (i.e., those identiﬁed at least annually from human clinical samples or closely
related species): M. tuberculosis, M. africanum, M. bovis, M. bovis strain BCG, M. avium, M. chelonae, M.
abscessus,M. fortuitum,M. gordonae,M. intracellulare,M. kansasii,M. malmoense,M. marinum,M. ulcerans,
and M. xenopi. In cases where the line probe assays used were known to be unable to distinguish
between certain species (i.e., M. chelonae/M. immunogenum, M. intracellulare/M. chimaera, M. fortui-
tum/M. mageritense, M. malmoense/M. palustre, and M. peregrinum/M. septicum), the results were con-
sidered concordant if WGS identiﬁed either species in the pair. Other rare species were reported
separately. Mixtures were also reported separately, but the results were considered concordant if any
species identiﬁed by LPA was also identiﬁed by WGS.
For TB drug resistance results, comparisons were made in two ways: (i) by comparing WGS
identiﬁcation of resistance-conferring mutations in the speciﬁc genes probed by the MTBDRplus test, i.e.,
inhA and katG for isoniazid resistance and rpoB for rifampin resistance, and (ii) by comparing the overall
WGS resistance prediction against the phenotypic DST result. Comparisons used binomial exact tests,
with the routine laboratory results considered the gold standard for both. MTBDRplus-identiﬁed resis-
tance was also compared to the phenotypic DST result.
Turnaround time for the routine laboratory was measured from the date the automated liquid culture
ﬂagged positive to the date the complete set of susceptibility phenotypes for ﬁrst-line drugs was
reported. For WGS, the start of the process was considered to be the date the aliquot was taken from the
MGIT tube. The WGS workﬂow consists of four main steps: extraction of DNA, sequencing of isolates (in
batches), download of data from the local sequencing machine to the central bioinformatics pipeline
(manually triggered), and processing of data in the pipeline to produce the clinical report. Since the WGS
infrastructure was substantially upgraded partway through the study, turnaround time was measured up
to the date the sequencing data arrived in the bioinformatics pipeline, and then the typical processing
time of the new pipeline was added. Comparisons were made using the Wilcoxon signed-rank test.
Accession number(s). The sequences reported in this paper have been deposited in the NCBI
Sequence Read Archive under BioProject number PRJNA401515.
RESULTS
Between 20 April 2015 and 31 March 2016, 2,204 liquid mycobacterial cultures of
clinical samples which signaled positive for mycobacterial growth at the Public Health
England National Mycobacterial Reference Service, Birmingham, United Kingdom, were
split by volume and processed both by conventional tests and by WGS. Of these, 33
isolates were used for WGS species algorithm training, and the remaining 2,171 isolates
(from 1,617 distinct patients) were eligible for inclusion in the study (Fig. 1). A total of
2,039 (93.9%) isolates were identiﬁed to the species or complex level by the routine
laboratory (using the GenoType MTBC, GenoType Mycobacterium CM, and GenoType
Mycobacterium AS line probe assays), and of these, 74 (3.6%) failed sequencing or WGS
species identiﬁcation (using Mykrobe v0.3 [21]), leaving 1,965 isolates available for
direct species comparison.
A total of 1,968 of the 2,039 isolates were identiﬁed by LPA as clinically important
mycobacterial species (Table 1), 46 were rarer species, and 25 were identiﬁed as
mixtures. A total of 1,902 of the 1,968 clinically important isolates had a WGS compar-
ator. Of the clinically important isolates, 1,825 (96.0% if excluding sequencing failures
and 92.7% if including sequencing failures) were identiﬁed as the same species by WGS
(Table 1; Fig. 2). Of the 77 cases where WGS identiﬁed a different species, 33 (42.9%)
isolates were identiﬁed as a different species within the same complex (6 MTBC, 3 M.
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abscessus complex, 7 M. avium complex, and 17 M. fortuitum complex isolates). In 26
cases, WGS identiﬁed a species not probed for by the Mycobacterium CM/AS tests
(Table 2). Fourteen of the discordant isolates were later found to have poor sequence
quality, e.g., low numbers of reads, low coverage of the reference genome, or a GC
content outside the range for mycobacteria. Detailed results for rarer species and
mixtures can be seen in Table S1 in the supplemental material.
Discordant isolates were retrieved from storage and retested by both methods.
Thirty-two (42%) discordant cases were resolved (15 in which the LPA result changed,
16 in which the WGS result changed, and 1 in which both results changed), 30 (39%)
FIG 1 Isolates included in the study, identiﬁed by MGIT culture between 20 April 2015 and 31 March
2016.
Quan et al. Journal of Clinical Microbiology
February 2018 Volume 56 Issue 2 e01480-17 jcm.asm.org 4
cases remained discordant (2 in which the LPA result changed, 6 in which the WGS
result changed, and 22 in which neither result changed), and 15 (19%) cases failed
retesting (Table S2).
A total of 2,157 LPA results (obtained using GenoType MTBDRplus) for inhA, katG,
and rpoB genes encoding resistance to the ﬁrst-line drugs isoniazid and rifampin were
available for 728 MTBC isolates. For DST, our WGS pipeline identiﬁes point mutations by
mapping isolates to an MTBC reference genome, and comparisons were made here by
using in silico predictions based only on the speciﬁc codons targeted by the LPA. In 216
(10.0%) cases, WGS failed to make a prediction due to insufﬁcient sequencing data.
Excluding these cases, the overall concordance was 99.3% (95% conﬁdence interval [CI],
98.9 to 99.6%), sensitivity was 97.6% (91.7 to 99.7%), and speciﬁcity was 99.5% (99.0 to
99.7%) (Table 3). Including the failures, the overall concordance was 89.4% (95% CI, 88.0
to 90.7%). By repeat testing of the 13 discordant isolates, four discordant cases were
resolved (with the MTBDRplus result changing in all four cases), four cases remained
discordant (one in which the MTBDRplus result changed and three in which neither
TABLE 1WGS species predictions compared to those of line probe assays
Organism identiﬁed by GenoType MTBC,
GenoType Mycobacterium CM, and








No. of isolates for which WGS
identiﬁed the same speciesa
(% excluding failures/%
including failures)







M. tuberculosis complex organisms
M. tuberculosis 778 31 (4.0) 743 (99.5/95.5) 4 0
M. africanum 8 0 (0.0) 7 (87.5/87.5) 1 0
M. bovis 8 0 (0.0) 6 (75.0/75.0) 1 1
M. bovis strain BCG 6 0 (0.0) 6 (100.0/100.0) 0 0
M. tuberculosis complex 13 0 (0.0) 13 (100.0/100.0) 0 0
Total 813 31 (3.8) 775 (99.1/95.3) 6 1
M. abscessus complex organisms
M. abscessus 157 4 (2.5) 152 (99.3/96.8) 0 1
M. chelonae 118 5 (4.2) 106 (93.8/89.8) 3 4
M. abscessus complex 5 1 (20.0) 3 (75.0/60.0) 0 1
Total 280 10 (3.6) 261 (96.7/93.2) 3 6
M. avium complex organisms
M. avium 258 0 (0.0) 252 (97.7/97.7) 0 6
M. intracellulare 328 8 (2.4) 296 (92.5/90.2) 7 17
Total 586 8 (1.4) 548 (94.8/93.5) 7 23
M. fortuitum complex organisms
M. fortuitum 42 1 (2.4) 24 (58.5/57.1) 15 2
M. peregrinum 11 4 (36.4) 4 (57.1/36.4) 2 1
Total 53 5 (9.4) 28 (58.3/52.8) 17 3
Other nontuberculous mycobacteria
M. gordonae 137 7 (5.1) 127 (97.7/92.7) 3
M. kansasii 36 2 (5.6) 32 (94.1/88.9) 2
M. malmoense 43 2 (4.7) 38 (92.7/88.4) 3
M. marinum 6 1 (16.7) 5 (100.0/83.3) 0
M. ulcerans 1 0 (0.0) 0 (0.0/0.0) 1
M. xenopi 13 0 (0.0) 11 (84.6/84.6) 2
Total 236 12 (5.1) 213 (95.1/90.3) 11
Total clinically important species 1,968 66 (3.4) 1,825 (96.0/92.7) 33 44
Rarer speciesb 46 6 (13.0) 11 (27.5/23.9)
Mixturesc 25 2 (8.0) 21 (91.3/84.0)
aIn cases where the line probe assays used were known to be unable to distinguish between certain species (i.e., M. chelonae/M. immunogenum, M. intracellulare/M.
chimaera, M. fortuitum/M. mageritense, M. malmoense/M. palustre, and M. peregrinum/M. septicum), the results were considered concordant if WGS identiﬁed either
species in the pair.
bRarer species include M. interjectum, M. scrofulaceum, M. genevense, M. goodii, M. lentiﬂavum, M. mucogenicum, M. simiae, and M. szulgai (see Table S1 in the
supplemental material).
cResults for mixtures were considered concordant if WGS identiﬁed at least one of the species reported by line probe assay (Table S1).
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result changed), and ﬁve isolates failed to regrow (Table S3). Of the four that remained
discordant, two were because the MTBDRplus test identiﬁed the wild type while WGS
consistently identiﬁed rpoB mutations encoding L430P and L452P changes. The re-
maining two instances of discordance can be considered “minor discordances,” as both
assays identiﬁed mutations at the same codon (rpoB_H445), with the only difference
being that the MTBDRplus result implied an amino acid mutation to aspartate (D) or
tyrosine (Y), whereas the WGS results indicated the presence of leucine (L) at this site.
All three amino acid substitutions are considered to cause resistance.
A total of 2,982 ﬁrst-line phenotypic DST results (using the Becton Dickinson MGIT
960 system) for 777 MTBC isolates were available for the drugs isoniazid, rifampin,
ethambutol, and pyrazinamide. This time, WGS predictions were made by comparing
any mutations found to our previously validated mutation catalogue (22). In 356
(11.9%) cases, WGS failed to make a prediction due to insufﬁcient sequencing data, and
in 154 (5.2%) cases, the WGS prediction was indeterminate due to the presence of
novel, previously uncharacterized mutations. Excluding these cases, the overall con-
FIG 2 WGS species prediction versus line probe assay results. The bars represent the species identiﬁed
by the line probe assay. (A) Concordance of WGS prediction at the species level. In cases where the line
probe assays used were known to be unable to distinguish between certain species (i.e., M. chelonae/M.
immunogenum, M. intracellulare/M. chimaera, M. fortuitum/M. mageritense, M. malmoense/M. palustre, and
M. peregrinum/M. septicum), the results were considered concordant if WGS identiﬁed either species in
the pair. (B) Isolates for which WGS identiﬁed a species different from that identiﬁed by the LPA.
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cordance was 99.2% (95% CI, 98.7 to 99.5%), sensitivity was 94.2% (88.4 to 97.6%), and
speciﬁcity was 99.4% (99.0 to 99.7%) (Table 4). Including the failures and indeterminate
predictions, the overall concordance was 82.2% (95% CI, 80.8 to 83.6%). In comparison,
the overall concordance of the MTBDRplus test and phenotypic isoniazid/rifampin DST
was 98.8% (98.1 to 99.3%), sensitivity was 84.0% (75.3 to 90.6%), and speciﬁcity was
100.0% (99.7 to 100.0%) (Table S4). Discordant isolates were not retested.
A total of 1,183 WGS predictions had corresponding susceptibility results from both
MTBDRplus testing and phenotypic DST for three-way comparison (Fig. 3). In all 51
TABLE 2 Clinically important isolates for which WGS identiﬁed a species different from that detected by LPAa














M. tuberculosis M. africanumc 4 3 (2) 0 1
M. africanum M. tuberculosisc 1 1 0 0
M. bovis M. bovis strain BCGc 1 1 0 0
M. bovis M. fortuitum 1 1 0 0
M. abscessus M. avium 1 1 (1) 0 0
M. chelonae M. tuberculosis 1 1 0 0
M. chelonae M. abscessusc 3 1 (1) 0 2
M. chelonae M. llatzerenseb 2 1 1 0
M. chelonae M. ratisbonenseb 1 0 1 0
M. abscessus complex M. llatzerenseb 1 0 0 1
M. avium M. tuberculosis 4 4 0 0
M. avium M. chelonae 1 1 0 0
M. avium M. shimoidei 1 1 (1) 0 0
M. intracellulare M. tuberculosis 2 1 1 0
M. intracellulare M. abscessus 1 0 0 1
M. intracellulare M. aviumc 1 0 0 1
M. intracellulare M. tuberculosis and M. aviumc 1 1 0 0
M. intracellulare M. gordonae 1 1 0 0
M. intracellulare M. arosienseb,c 1 0 1 0
M. intracellulare M. colombienseb,c 2 0 2 0
M. intracellulare M. marseillenseb,c 2 0 2 0
M. intracellulare M. parafﬁnicum 3 0 2 1
M. intracellulare M. tomidaeb 9 1 6 2
M. intracellulare M. triplexb 1 0 1 0
M. fortuitum M. chelonae 1 0 1 0
M. fortuitum M. gordonae 1 0 0 1
M. fortuitum M. peregrinumc 5 5 (5) 0 0
M. fortuitum M. septicumc 5 0 4 1
M. fortuitum M. farcinogenesb,c 1 0 1 0
M. fortuitum M. porcinumb,c 4 0 4 0
M. peregrinum M. kansasii 1 0 1 0
M. peregrinum M. farcinogenesb,c 2 0 2 0
M. gordonae M. tuberculosis 1 0 0 1
M. gordonae M. avium 1 1 (1) 0 0
M. gordonae M. intracellulare 1 0 0 1
M. kansasii M. tuberculosis 1 1 (1) 0 0
M. kansasii M. malmoense 1 1 (1) 0 0
M. malmoense M. tuberculosis 1 1 0 0
M. malmoense M. chimaera 1 0 0 1
M. malmoense M. intracellulare 1 0 0 1
M. ulcerans M. marinum 1 1 (1) 0 0
M. xenopi M. abscessus 1 1 (1) 0 0
M. xenopi M. tuberculosis and M. avium 1 1 0 0
Total 77 32 (15) 15 30
aDetailed results for the repeat tests can be seen in Table S2 in the supplemental material. Note that the M. tuberculosis complex includes M. tuberculosis, M.
africanum, M. bovis, and M. bovis strain BCG, the M. abscessus complex includes M. abscessus and M. chelonae, the M. avium complex includes M. avium, M.
intracellulare, M. chimaera, M. arosiense, M. colombiense, and M. marseillense, and the M. fortuitum complex includes M. fortuitum, M. mageritense, M. peregrinum, M.
septicum, M. porcinum, and M. farcinogenes.
bOrganism not in Mycobacterium CM/AS catalogue.
cOrganism is in the same complex as the LPA-identiﬁed species.
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cases where the WGS prediction was indeterminate (i.e., found only uncharacterized
mutations), the isolate was phenotypically susceptible. In 9/11 (82%) cases where WGS
predicted resistance and MTBDRplus testing did not, the phenotype was resistant
(mutations found in phenotypically resistant isolates were katG_S315T [two times],
katG_W328L [two times], rpoB_L452P [two times], rpoB_V170F [two times], and
rpoB_H445L, and mutations found in phenotypically susceptible isolates were
rpoB_L452P and rpoB_L430P; among these, MTBDRplus testing does not probe for
katG_W328 or rpoB_V170 mutations). In the 4 cases where WGS predicted susceptibility
and the phenotype was resistant, the MTBDRplus result did not indicate a resistance
mutation either.
The turnaround time for all four ﬁrst-line phenotypic DST results was available for
427 MTBC isolates. For these isolates, the median processing time for the routine
laboratory was 20 days (interquartile range [IQR], 15 to 31 days), similar to the median
processing time for WGS (21 days) (IQR, 15 to 23 days) (P  0.41). However, perfor-
mance varied noticeably across the 1-year study period, with WGS being faster in the
ﬁrst 6 months (median difference, 4 days faster [IQR, 3 to 12 days]; P  0.001) and
slower in the last 6 months (median difference, 7 days slower [IQR, 15 to 7.5 days];
P 0.009). There was substantial variation in the time taken for three of the main steps
in the WGS workﬂow (extraction of DNA, sequencing of isolates [in batches], and
download of data from the local sequencing machine to the central bioinformatics
pipeline [manually triggered]), with delays occurring in different stages depending on
the period (Fig. 4). At its fastest, the processing time for the laboratory was around 8
days.
DISCUSSION
In this large prospective study, we showed that WGS can be performed routinely in
a high-throughput laboratory and that when predictions are made, they achieve very
high agreement with current diagnostic tests for both mycobacterial species identiﬁ-
cation (96.0%) and MTBC ﬁrst-line drug resistance detection (99.3% versus LPA and
99.2% versus phenotypic testing). About half of the differences in species identiﬁcation
were resolved on repeat testing, suggesting that they were possibly caused by labo-
FIG 3 WGS susceptibility predictions versus those of MTBDRplus and phenotypic testing for the drugs
isoniazid and rifampin. R, resistant; S, susceptible; U, uncharacterized mutations found. MTBDRplus results
were treated as resistant if the result was mutation or loss of wild type. The MTBDRplus test does not
claim to predict susceptibility (only the absence of known resistance mutations), but we labeled
MTBDRplus “wild type” calls “susceptible” in order to aid comparisons.
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ratory errors or mixtures. There were continued differences after repeat testing for
species identiﬁed by line probe assays as M. fortuitum, M. peregrinum, M. intracellulare,
or M. chelonae, suggesting that these particular species should be the focus of further
work.
Nearly half (13/30 isolates) of the isolates with persistent differences between WGS
and line probe-based species identiﬁcation methods were identiﬁed by routine tests as
M. fortuitum or M. peregrinum, both of which are members of the M. fortuitum complex,
which contains 12 different species. In all these cases, WGS identiﬁed another species
within the same complex (but not present in the LPA catalogues) either before or after
the repeat test. The Mycobacterium CM test splits this complex into two groups and
may not differentiate them well due to similarity between sequences in the target sites
(12). More accurate identiﬁcation of the members of this complex to the species level
may become clinically important in the future (24, 25).
Fifteen of the isolates with persistently discordant results at the species level were
identiﬁed by the routine laboratory as M. intracellulare. Five of these were identiﬁed by
WGS as other species within the M. avium complex (not including M. chimaera, which
was treated as concordant with M. intracellulare since the Mycobacterium CM test does
not distinguish between the two), and a recent study found that the Mycobacterium
CM test often misidentiﬁes rare M. avium complex species as M. intracellulare (26). A
further seven isolates were classiﬁed as M. tomidae by WGS. The strain on which this
classiﬁcation was based was obtained from the National Collection of Type Cultures
catalogue and is incorporated in the Mykrobe species classiﬁer (21), part of the WGS
bioinformatics pipeline. It appears that this particular strain has been catalogued
variously as M. intracellulare (27), M. szulgae (28), and M. neoaurum (ATCC 23069; DSM
43993), suggesting that it is probably not reliable enough to be used as an exemplar
in future. However, WGS consistently mapped these seven discordant isolates (in a
workﬂow stream separate from the Mykrobe classiﬁcation) to M. intracellulare, suggest-
ing that the routine laboratory result was correct.
The two persistently discordant isolates that routine tests identiﬁed as M. chelonae
were identiﬁed as M. llatzerense and M. ratisbonense by WGS. To the best of our
FIG 4 Differences in processing times for complete ﬁrst-line susceptibility reporting for MTBC isolates.
The horizontal line shows the median processing time for the routine laboratory, starting from the date
that the MGIT tube was ﬂagged as positive. The vertical lines show the different stages in the WGS
process, starting from the removal of an aliquot from the positive MGIT tube. The WGS infrastructure was
substantially upgraded partway through the study, with original report dates unavailable, so the typical
processing time (1 day) of the new pipeline was used instead. Each line represents one isolate.
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knowledge, M. ratisbonense has previously been reported only from sewage (29). Given
the continuing discovery and sequencing of rare mycobacteria, species identiﬁcation
catalogues should be updated regularly. WGS is reliant on the completeness and
accuracy of sequence databases, which should not automatically be assumed to be
error-free; therefore, in practice, surprising results such as these should be treated with
caution and potentially veriﬁed using an alternative method.
In cases where predictions were made, the agreement between line probe assay,
phenotyping, and WGS results for ﬁrst-line drug resistance predictions was remarkably
high. Similar results were recently reported for 462 prospectively collected MTBC
isolates in the New York State Reference Laboratory (19); however, that U.S. study did
not use WGS to identify mycobacterial species beyond differentiating MTBC from NTM
isolates. One question is how isolates that failed WGS (denoted “F” in Tables 3 and 4)
or had previously uncharacterized mutations (“U”) should be considered in calculating
concordance. It can be argued that excluding them introduces a bias in favor of WGS,
but on the other hand, including them creates a bias against WGS because there are
two types of error to consider here: making an incorrect prediction versus not making
a prediction at all. Including failures and uncharacterized mutations as automatically
discordant makes the two errors indistinguishable, when in practice they are not the
same. The former error would cause a clinician to make an error in management,
whereas the latter indicates a lack of certainty which can then be managed clinically,
similarly to a “loss of wild type” prediction from the MTBDRplus test, or by further
testing. Note that, in this study, all but one isolate with previously uncharacterized
mutations were phenotypically susceptible, and our deﬁnition of “failure” was very
strict, requiring complete information at every base previously associated with resis-
tance in relevant resistance-associated genes. The fact that WGS is still a new and
improving technology means that the proportion of failures is likely to decrease in the
coming years.
The turnaround time compared to that for phenotypic DST was not as short as
expected, though still comparable, but this was not a true “real-time” head-to-head
comparison, since the WGS analysis platform was still under development while the
study isolates were being collected and sequenced, and the WGS processing was
secondary in priority to the routine laboratory workﬂow. Now that WGS is in routine
clinical use in the same laboratory, the current estimate for WGS turnaround time
starting from MGIT positivity (measured over 4 weeks in May 2017) is around 7 days
(E. G. Smith, personal communication), compared to 15 days in the New York State
Reference Laboratory study (19), which is still 9 days earlier than that for their conven-
tional methods. WGS is clearly slower than Hain LPAs (which typically return results the
same day for a positive MGIT isolate), but this will continue to improve as the process
matures and may be cut dramatically further if sequencing directly from samples
becomes a reality (30).
This study had several limitations. It was conducted at only a single site, but this site
is a large reference laboratory receiving isolates from multiple hospitals, and we
previously showed that the extraction and sequencing process can be followed suc-
cessfully at 17 sites internationally (16). Test results from the routine laboratory work-
ﬂow were missing for a small proportion of isolates, and not all the isolates which
showed discordant results were able to be regrown and retested. However, there is no
reason to believe that this would lead to bias toward WGS. Although the isolates with
discordant results had been stored at 20°C for several months and the repeat tests
were carried out on fresh subcultures rather than on the original cultures, nevertheless,
around half the discrepancies were resolved on repeat testing, suggesting that labo-
ratory errors, intrinsic variability, or the presence of nonmycobacterial DNA in the
original culture were responsible for much of the initial discordance. We did not carry
out a cost analysis as part of this study but have shown previously that WGS-based
diagnostics can actually be more cost-effective than routine workﬂows for a mycobac-
terial reference center (16).
As WGS is still a fairly new technology, it should be expected that some aspects of
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its implementation will need improvement, in particular increasing the proportion of
predictions made as well as highlighting results that require further interpretation or
repeat testing. The WGS predictions are deliberately conservative but can be reﬁned
further as more data accrue, particularly with respect to characterizing the effects of
novel, potentially resistance-conferring mutations on DST predictions. As more NTM
strains are sequenced, the phylogeny and relationships between species may change,
along with their associations with clinical disease (23) and their antibiotic resistance
proﬁles (31, 32). However, when predictions are made by WGS, they are very accurate,
and as the rate of NTM infections rises, the increased information that WGS offers can
only become more valuable.
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